Journal of Advances in Nanomaterials

Download PDF (829.1 KB) PP. 20 - 30 Pub. Date: March 3, 2017

DOI: 10.22606/jan.2017.21003

• Xin-Hua Tian^*
  Department of Neurosurgery, Zhongshan Hospital, Xiamen University, Xiamen, China
• Yu-Hua Wang
  
  Department of Neurosurgery, Zhongshan Hospital, Xiamen University, Xiamen, China
• Feng Wei
  
  Department of Neurosurgery, Zhongshan Hospital, Xiamen University, Xiamen, China
• Xiao-Ning Lin
  
  Department of Neurosurgery, Zhongshan Hospital, Xiamen University, Xiamen, China
• Lei Ren
  
  Research Center of Biomedical Engineering, Department of Biomaterials, College of Materials; State Key Laboratory for Physical Chemistry of Solid Surfaces, Xiamen University, Xiamen, China

An excellent gene vector is of great importance for the development of the gene therapy. Gelatin–siloxane nanoparticles (GS NPs) with controlled size and surface charge were synthesized through a two-step sol–gel process for gene vector. In order to increase the efficiency of tumour targeting, HIV-derived Tat peptide and TTA1, a kind of modified RNA aptamer, were further grafted onto GS NPs (GS-PEG-TTA1/TAT NPs). It was demonstrated in this article that gelatin-siloxane nanoparticles (GS NPs) have the significant characteristic of being innocuous, small, covered with positive charge and even have been modified with PEG, TTA1, and TAT. The modified nanoparticles, GS-PEG-TTA1/TAT, not only have the ability of crossing the cell membrane with DNA accompanied effectively, but also could target the U251 cells and impel the DNA express right in the cells with the help of aptamer TTA1.

Nanoparticles, peptide, blood–brain barrier, brain targeting

[1] Yi D, Hua TX, Lin HY, et al. Antitumor treatment efficacy by targeting epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in an orthotopic human glioblastoma model. J Neurooncol. 2011; 104(1):93-101.

[2] Gwak HS, Youn SM, Kwon AH, et al. ACNU-cisplatin continuous infusion chemotherapy assalvage therapy for recurrent glioblastomas: phase II study. J Neurooncol. 2005;75(2):173–180.

[3] Liu L, Guo K, Lu J, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials. 2008;29(10):1509-17.

[4] Chen YZ, Yao XL, Tabata Y, Nakagawa S, Gao JQ. Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy. Clin Dev Immunol. 2010;2010:565643.

[5] Vetrini F, Ng P.Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses. 2010;2(9):1886-917.

[6] Fulci G, Chiocca EA.The status of gene therapy for brain tumors. Expert Opin Biol Ther. 2007;7(2):197-208.

[7] Tros de Ilarduya C, SunY, Düzgüne? N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci. 2010;40(3):159-70.

[8] Tian XH, Lin XN, Wei F, et al. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine. 2011;6:445–452.

[9] Kreuter J, Ulbrich K, Hekmatara T, Herbert E. Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB). Eur J Pharm Biopharm. 2009;71(2):251–256

[10] R. Fischer, M. Fotin-Mleczek, H. Hufnagel, R. Brock, Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptides, Chembiochem.2005;6(12):2126–2142.

[11] Ko HY, Choi KJ, Lee CH, Kim S.A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin αvβ3 and tenascin-C proteins. Biomaterials. 2011;32(4):1130-8

[12] Wurster SE, Bida JP, Her YF, Maher 3rd LJ. Characterization of anti-NF-kappaB RNA aptamer-binding specificity in vitro and in the yeast three-hybrid system. Nucleic Acids Res. 2009;37(18):6214-6224.

[13] Li Y, Lee HJ, Corn RM. Fabrication and characterization of RNA aptamer microarrays for the study of protein-aptamer interactions with SPR imaging. Nucleic Acids Res. 2006;34(22):6416-6424.

[14] Midwood KS, Hussenet T, Langlois B, Orend G.Advances in tenascin-C biology. Cell Mol Life Sci. 2011;68(19):3175-99

[15] Kim MY, Kim OR, Choi YS, Lee H, Park K, Lee CT, Kang KW, Jeong S. Selection and characterization of tenascin C targeting peptide. Mol Cells. 2012;33(1):71-77

[16] Wang ZY., Zhao Y, Ren L, et al. Novel gelatin-siloxane nanoparticles decorated by Tat peptide as vectors for gene therapy[J]. Nanotechnology. 2008, 19(44):445103.

[17] Yin P, Wang J, Ren L, et al. Conjugation of membrane-destabilizing peptide onto gelatin-siloxane nanoparticles for efficient gene expression, Materials Science & Engineering C-Materials for Biological Applications.2010;30(8):1260-1265.

[18] Motegi H, Kamoshima Y, Terasaka S, et al. A novel adherent culture method of glioblastoma cells expressing CD133 using collagen-1-coated plates. Hokkaido Igaku Zasshi. 2012;87(4-5):147-151.

[19] Kurozumi K, Ichikawa T, Onishi M, et al. Cilengitide treatment for malignant glioma: current status and future direction. Neurol Med Chir (Tokyo). 2012;52(8):539-547.

[20] Wang L, Zhao H, Cui K, et al. Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening. Biosci Trends. 2012; 6(4):192-200.

[21] Ranki T, Hemminki A. Serotype chimeric human adenoviruses for cancer gene therapy. Viruses. 2010;2(10):2196-212.

[22] Hicke BJ , Stephens AW, Gould T, et al. Tumor targeting by an aptamer. The Journal Of Nuclear Medicine.2006,47(4):668–768.

[23] Hicke BJ, M arion C, Chang YF, et al. Tenascin-c aptamers are generated using tumor cells and purified protein. J Biol Chem. 2001;276:48644–48654.

[24] Daniels DA , C hen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-c aptamer identified by tumor cell SELEX: systemat ic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA.2003;100(26):15416–15421.

[25] Eguchi, A., Akuta, T., Okuyama, H., et al. Protein transduction domain of HIV-1 TAT protein promotes efficient delivery of DNA into mammalian cells. J. Biol. Chem. 2001;276(28), 26204–26210.

[26] Agarwal A, Lariya N, Saraogi G, et al. Nanoparticles as novel carrier forbrain delivery: a review. Curr Pharm Des, 2009,15(8): 917-925.

[27] Zhi Ping Xu, Qing Hua Zeng, Gao Qing Lu, Ai Bing Yu. Inorganic nanoparticles as carriers for efficient cellular delivery. Chemical Engineering Science. 2006, 61,(3):1027–1040

[28] Paul A, Binsalamah ZM, Khan AA, et al. A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy. Biomaterials. 2011;32(32):8304-8318.

[29] Lee SJ, Yoon SH, Doh KO. Enhancement of gene delivery using novel homodimeric tat peptide formed by disulfide bond. J Microbiol Biotechnol. 2011;21(8):802-807.

[30] Chung TH, Wu SH, Yao M, et al. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials. 2007;28(19):2959-66.

[31] Liu L, Guo K, Lu J, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials. 2008;29(10):1509-17.

[32] Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein trans-duction: delivery of a biologically active protein into the mouse. Science. 1999;285(5433):1569-1572.

[33] Arjen van den Berg and Steven F Dowdy. Protein transduction domain delivery of therapeutic macromolecules. Current Opinion in Biotechnology. 2011, 22(6):888-893.

[34] Qin Y, Chen H, Yuan W, et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm. 2011;419(1-2):85-95.